Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Biologic agents in psoriasis.

Michael R Lee¹, Alan J Cooper

¹Department of Dermatology, Royal North Shore Hospital, Pacific Highway, St Leonards, New South Wales, Australia. mick155@bigpond.net.au

The Australasian Journal of Dermatology

|October 13, 2006

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mesopotamian ancient DNA reveals Iron Age integration of heterogeneous Bronze Age genetic ancestries following resettlement.

Genome biology·2026

Same author

A tiered secondary poisoning risk assessment approach to prevent unnecessary fish bioaccumulation testing of pharmaceuticals.

Regulatory toxicology and pharmacology : RTP·2026

Same author

Revisiting Visual Criteria of the Ideal Neck in the Young Caucasian Female.

Aesthetic surgery journal·2025

Same author

Evaluation of the EMA log kow trigger for fish BCF testing based on data for several human pharmaceuticals.

Regulatory toxicology and pharmacology : RTP·2024

Same author

Commentary on: Developing the Aesthetic Postoperative Complication Score (APeCS) for Detecting Major Morbidity in Facial Aesthetic Surgery.

Aesthetic surgery journal·2024

Same author

Commentary on: The Ponytail Lift: 22 Years of Experience in 600 Cases of Endoscopic Deep Plane Facial Rejuvenation.

Aesthetic surgery journal·2024

Same journal

Dupilumab-Associated Erythema Multiforme-Like Eruption With Lichenoid Histology in a Paediatric Patient: A Case Report.

The Australasian journal of dermatology·2026

Same journal

Contact Allergens Relevant to LGBTQI Populations: A Narrative Review and Practical Considerations.

The Australasian journal of dermatology·2026

Same journal

A Retrospective Review of Scabies Cases Managed by the Dermatology Department in a North Queensland Hospital Over a 10-Month Period.

The Australasian journal of dermatology·2026

Same journal

Telangiectasia in Systemic Sclerosis Is a Marker of Increased Disease Morbidity and Mortality: Analyses From the Australian Scleroderma Cohort Study.

The Australasian journal of dermatology·2026

Same journal

Allergic Contact Dermatitis Caused by Online-Purchased Black Henna Temporary Tattoos.

The Australasian journal of dermatology·2026

Same journal

Alpelisib for TEK- and PIK3CA-Related Venous Malformations: A Systematic Review.

The Australasian journal of dermatology·2026

See all related articles

This review covers new biologic therapies for psoriasis that target immune system pathways. It examines monoclonal antibodies, fusion proteins, and recombinant cytokines, detailing their actions, effectiveness, and side effects.

Area of Science:

Immunology
Dermatology
Pharmacology

Background:

Psoriasis pathogenesis involves complex immunologic steps.
Targeting these steps offers a novel therapeutic approach.

Purpose of the Study:

To review new biologic agents for psoriasis.
To analyze strategies targeting immunologic pathways in psoriasis.
To discuss the actions, efficacy, and side effects of specific biologic agents.

Main Methods:

Review of scientific literature on biologic agents for psoriasis.
Categorization of agents by therapeutic strategy (T-cell reduction, T-cell inhibition, immune modulation, cytokine blockade).
Classification of agents by type (monoclonal antibodies, fusion proteins, recombinant cytokines/growth factors).

Related Experiment Videos

Main Results:

Four main strategies are targeted in biologic therapy for psoriasis.
Biologic agents include monoclonal antibodies, fusion proteins, and recombinant cytokines/growth factors.
Specific agents reviewed: alefacept, efalizumab, etanercept, and infliximab.

Conclusions:

Biologic agents represent a significant advancement in psoriasis treatment.
Understanding their mechanisms, efficacy, and side effects is crucial for clinical application.
Further research into optimizing these targeted therapies is warranted.